RetusamineCAS# 6883-16-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 6883-16-5 | SDF | Download SDF |
| PubChem ID | 165551 | Appearance | Cryst. |
| Formula | C19H25NO7 | M.Wt | 379.41 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CCC12C(C(C(=O)OCC3=CC[N+]4(C3(C(CC4)OC1=O)O)C)(OC2=O)C)C | ||
| Standard InChIKey | ZNDNHSZHGPQSBN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H26NO7/c1-5-18-11(2)17(3,27-16(18)23)14(21)25-10-12-6-8-20(4)9-7-13(19(12,20)24)26-15(18)22/h6,11,13,24H,5,7-10H2,1-4H3/q+1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Retusamine is a natural product from Crotalaria pallida. |
| In vitro | Hepato- and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure.[Pubmed: 1253333]Chem Biol Interact. 1976 Mar;12(3-4):299-324.
|
Retusamine Dilution Calculator
Retusamine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6357 mL | 13.1784 mL | 26.3567 mL | 52.7134 mL | 65.8918 mL |
| 5 mM | 0.5271 mL | 2.6357 mL | 5.2713 mL | 10.5427 mL | 13.1784 mL |
| 10 mM | 0.2636 mL | 1.3178 mL | 2.6357 mL | 5.2713 mL | 6.5892 mL |
| 50 mM | 0.0527 mL | 0.2636 mL | 0.5271 mL | 1.0543 mL | 1.3178 mL |
| 100 mM | 0.0264 mL | 0.1318 mL | 0.2636 mL | 0.5271 mL | 0.6589 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sempervirine
Catalog No.:BCN4250
CAS No.:6882-99-1
- Sophoridine
Catalog No.:BCN4249
CAS No.:6882-68-4
- Dihydrochelerythrine
Catalog No.:BCN2273
CAS No.:6880-91-7
- Norfluorocurarine
Catalog No.:BCN4811
CAS No.:6880-54-2
- 6-Acetyl-2,2-dimethylchroman-4-one
Catalog No.:BCN4248
CAS No.:68799-41-7
- 4-Oxobedfordiaic acid
Catalog No.:BCN4247
CAS No.:68799-38-2
- Dipotassium glycyrrhizinate
Catalog No.:BCN8487
CAS No.:68797-35-3
- Dehydroeburicoic acid
Catalog No.:BCN3646
CAS No.:6879-05-6
- Tuberstemonine
Catalog No.:BCN4986
CAS No.:6879-01-2
- Triclabendazole
Catalog No.:BCC4742
CAS No.:68786-66-3
- 1beta-Hydroxyalantolactone
Catalog No.:BCN3508
CAS No.:68776-47-6
- 12-Hydroxy-2,3-dihydroeuparin
Catalog No.:BCN8115
CAS No.:68776-42-1
- D-Prolinol(oil)
Catalog No.:BCC2708
CAS No.:68832-13-3
- 4-Epi-isoinuviscolide
Catalog No.:BCN4251
CAS No.:68832-39-3
- IWP 12
Catalog No.:BCC5622
CAS No.:688353-45-9
- Xanthohumol I
Catalog No.:BCN8016
CAS No.:688360-06-7
- Xanthohumol L
Catalog No.:BCN8017
CAS No.:688360-15-8
- Astemizole
Catalog No.:BCC7691
CAS No.:68844-77-9
- Boc-D-Tyr(Me)-OH
Catalog No.:BCC2597
CAS No.:68856-96-2
- Fmoc-Val-OH
Catalog No.:BCC3570
CAS No.:68858-20-8
- HMP Linker
Catalog No.:BCC2832
CAS No.:68858-21-9
- 8-O-Methylretusin-7-O-beta-D-glucopyranoside
Catalog No.:BCN7899
CAS No.:68862-13-5
- Otonecine
Catalog No.:BCN2009
CAS No.:6887-34-9
- Eburicol
Catalog No.:BCN4252
CAS No.:6890-88-6
Hepato- and pneumotoxicity of pyrrolizidine alkaloids and derivatives in relation to molecular structure.[Pubmed:1253333]
Chem Biol Interact. 1976 Mar;12(3-4):299-324.
62 pyrrolizidine alkaloids and derivatives have been screened for acute and chronic hepato- and pneumotoxicity by the single dose method previously described. This procedure is satisfactory for the compounds of medium to high hepatotoxicity but failed to detect toxicity in certain other compounds of known, low hepatotoxicity. New findings significant in relation to hepatotoxicity are as follows: (i) On a molar basis, diesters of heliotridine and retronecine are about 4 times as toxic as the respective mono-esters and heliotridine esters are 2-4 times as toxic as retronecine esters. (ii) Crotanecine esters are less toxic than retronecine esters, and the 6,9-diester madurensine, 2-4 times less toxic than the 7,9-diester anacrotine (the difference being ascribed to there being only one reactive alkylating centre in the toxic metabolite from madurensine). (iii) Hepatotoxicity was confirmed for 7-angelylheliotridine but not observed for 9-angelyheliotridine and 7- and 9-angelylretronecine. (iv) Other significant compounds failing to induce hepatotoxicity were 9-pivalyl- and 7,9-dipivalyheliotridine, the alpha- and beta-epoxides of monocrotaline, 7-angelyl-1-methylenepyrrolizidine and the methiodides of monocrotaline and senecionine. The following compounds are readily converted by rat liver microsomes in vitro into dehydroheliotridine (or dehydroretronecine): 7- and 9-angelyheliotridine, 7- and 9-angelylretronecine, 7,9-dipivalylheliotridine and otosenine. 7,9-Divalerylheliotridine, the alpha- and beta-epoxides of monocrotaline, and Retusamine yield pyrrolic metabolites more slowly. The preparation and characterisation of several alkaloid derivatives are described. Chronic lung lesions were produced by most compounds which gave chronic liver lesions, although a higher dose was required in some instances. This requirement may sometimes mean that chronic lung lesions cannot be induced because of the intervention of acute or peracute deaths. Apart from this factor, structure activity requirements for pneumotoxicity are the same as for hepatotoxicity, consistent with their being both caused by the same toxic metabolites.
